Frontlight ResearchEarly access
Not yet taking people in ItalyPhase 1
Testing a new targeted radioactive drug for advanced prostate cancer
Tests a targeted radioactive drug in adults with metastatic prostate cancer.
Key facts
- Who runs it
- Fondazione IRCCS Istituto Nazionale Dei Tumori
- Where
- Milan, ItalySee the site
- Trial code
- Registry title
- Clinical study to evaluate the safety and efficacy of a new targeted radioactive drug treatment for advanced prostate cancer
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 5 people, planned
- Started
- 30 Oct 2026
- Expected to end
- 30 Mar 2027
- Type of study
- Interventional
- Record updated
- 15 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult men with advanced prostate cancer that has spread. It tests a new targeted radioactive drug.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Advanced prostate cancer that has spread (metastatic)
Where in Italy
- Fondazione IRCCS - Istituto Nazionale dei TumoriMilan, ItalyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Testing a new targeted radioactive drug for advanced prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 15 September 2026